Subclinical cardiovascular disease parameters after one year in new users of depot medroxyprogesterone acetate compared to copper-IUD

References

• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–322.
   PubMed Web of Science ®Google Scholar
• Wilmot KA, O’Flaherty M, Capewell S, et al. Coronary heart disease mortality declines in the United States from 1979 through 2011: evidence for stagnation in young adults, especially women. Circulation. 2015;132:997–1002.
   PubMed Web of Science ®Google Scholar
• Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association. J Am Coll Cardiol. 2011;57:1404–1423.
   PubMed Web of Science ®Google Scholar
• Garcia M, Mulvagh SL, Merz CN, et al. Cardiovascular disease in women: clinical perspectives. Circ Res. 2016;118:1273–1293.
   PubMed Web of Science ®Google Scholar
• Alkema L, Kantorova V, Menozzi C, et al. National, regional, and global rates and trends in contraceptive prevalence and unmet need for family planning between 1990 and 2015: a systematic and comprehensive analysis. Lancet. 2013;381:1642–1652.
   PubMed Web of Science ®Google Scholar
• Kaunitz AM. Long-acting contraceptive options. Int J Fertil Menopausal Stud. 1996;41:69–76.
   PubMedGoogle Scholar
• Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2004;47:277–283.
   PubMed Web of Science ®Google Scholar
• Hellman L, Yoshida K, Zumoff B, et al. The effect of medroxyprogesterone acetate on the pituitary-adrenal axis. J Clin Endocrinol Metab. 1976;42:912–917.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO; 2015; [cited 2017 Aug 24]. Available from: http://apps.who.int/iris/bitstream/10665/181468/1/9789241549158_eng.pdf?ua=1
   Google Scholar
• Liew DF, Ng CS, Yong YM, et al. Long-term effects of Depo-Provera on carbohydrate and lipid metabolism. Contraception. 1985;31:51–64.
   PubMed Web of Science ®Google Scholar
• Enk L, Landgren BM, Lindberg UB, et al. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids. Horm Metab Res. 1992;24:85–89.
   PubMed Web of Science ®Google Scholar
• Kongsayreepong R, Chutivongse S, George P, et al. A multicentre comparative study of serum lipids and apolipoproteins in long-term users of DMPA and a control group of IUD users. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation Special Programme of Research, Development and Research Training in Human Reproduction. Contraception. 1993;47:177–191.
   PubMedGoogle Scholar
• Dilshad H, Yousuf RI, Shoaib MH, et al. Cardiovascular disease risk associated with the long-term use of depot medroxyprogesterone acetate. Am J Med Sci. 2016;352:487–492.
   PubMed Web of Science ®Google Scholar
• Sorensen MB, Collins P, Ong PJ, et al. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation. 2002;106:1646–1651.
   PubMed Web of Science ®Google Scholar
• Lizarelli PM, Martins WP, Vieira CS, et al. Both a combined oral contraceptive and depot medroxyprogesterone acetate impair endothelial function in young women. Contraception. 2009;79:35–40.
   PubMed Web of Science ®Google Scholar
• Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23:1–87.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214–E223.
   PubMed Web of Science ®Google Scholar
• Nash HA. Depo Provera: a review. Contraception. 1975;12:377–393.
   PubMed Web of Science ®Google Scholar
• Amatayakul K. The effects of depo-provera on carbohydrate, lipids and vitamin metabolism. J Steroid Biochem. 1979;11:475–481.
   PubMedGoogle Scholar
• Leon-Acuña A, Alcala-Diaz JF, Delgado-Lista J, et al. Hepatic insulin resistance both in prediabetic and diabetic patients determines postprandial lipoprotein metabolism: from the CORDIOPREV study. Cardiovasc Diabetol. 2016;15:68.
   PubMed Web of Science ®Google Scholar
• Klempfner R, Erez A, Sagit BZ, et al. Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease: twenty-two-year follow-up of the Bezafibrate Infarction Prevention Study. Circ Cardiovasc Qual Outcomes. 2016;9:100–108.
   PubMed Web of Science ®Google Scholar
• Virutamasen P, Wongsrichanalai C, Tangkeo P, et al. Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study. Int J Gynaecol Obstet. 1986;24:291–296.
   PubMed Web of Science ®Google Scholar
• Crona N, Enk L, Samsioe G, et al. High-dose depot-medroxyprogesterone acetate (DMPA) – effects on lipid and lipoprotein metabolism. Eur J Obstet Gynecol Reprod Biol. 1983;16:97–105.
   PubMed Web of Science ®Google Scholar
• Segall-Gutierrez P, Xiang AH, Watanabe RM, et al. Deterioration in cardiometabolic risk markers in obese women during depot medroxyprogesterone acetate use. Contraception. 2012;85:36–41.
   PubMed Web of Science ®Google Scholar
• Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med. 2004;255:188–205.
   PubMed Web of Science ®Google Scholar
• Garza-Flores J, De la Cruz DL, Valles de Bourges V, et al. Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolism. Contraception. 1991;44:61–71.
   PubMed Web of Science ®Google Scholar
• Graff-Iversen S, Tonstad S. Use of progestogen-only contraceptives/medications and lipid parameters in women age 40 to 42 years: results of a population-based cross-sectional Norwegian Survey. Contraception. 2002;66:7–13.
   PubMed Web of Science ®Google Scholar
• Fåhraeus L, Sydsjö A, Wallentin L. Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate. Fertil Steril. 1986;45:503–506.
   PubMed Web of Science ®Google Scholar
• Bakry S, Merhi ZO, Scalise TJ, et al. Depot-medroxyprogesterone acetate: an update. Arch Gynecol Obstet. 2008;278:1–12.
   PubMed Web of Science ®Google Scholar
• World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. Contraception. 1998;57:315–324.
   PubMed Web of Science ®Google Scholar